ArticleVaccine2017
A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naïve pigs under experimental conditions.
Article in Vaccine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- Safety and reproductive performance in sows after vaccination: a randomized controlled trial.Veterinary research communications · 2026Article
- Outbred mice as an appropriate model for evaluating the immunogenicity of vaccines against porcine circovirus 2.Open veterinary journal · 2026Article
- A porcine circovirus type 2d-based virus-like particle subunit vaccine effectively protects pigs against homologous challenge.Frontiers in microbiology · 2026Article
- Article
- Speculative Review on the Feasibility of Porcine Circovirus 2 Elimination.Animals : an open access journal from MDPI · 2025Review
- Global dynamics of vaccine effectiveness and genotype shift in porcine circovirus 2: A cross-temporal analysis.Open veterinary journal · 2025Article
- Evaluation of PCV2 vaccine immunogenicity and efficacy using ELISpot to detect virus-specific memory B cells.Porcine health management · 2025Article
- Cellular immune signatures and differences of four porcine circovirus type 2 vaccines to heterologous PCV2d infection.NPJ vaccines · 2025Article
- Non-Compromised Efficacy of the First Commercial Ready-to-Use Genotype 2d Porcine Circovirus Type 2 andViruses · 2025Article
- TLR Agonist Immunoadjuvants Provide Effective Protection Against PCV2 and PRV Infections in a Bivalent Subunit Vaccine for PCV2 and PRV.Veterinary sciences · 2025Article
- Prevalence of pathogens from clinical samples associated with porcine respiratory and digestive diseases in South Korea from 2021 to 2023.Frontiers in veterinary science · 2025Article
- The Decade of Porcine Circovirus Type 2 (PCV2) in Thailand: Phylodynamic and Molecular Epidemiology.Transboundary and emerging diseases · 2025Article
- Synthesis and characterization of molecularly imprinted polymer nanoparticles against porcine circovirus type 2 viral-like particles.Analytical and bioanalytical chemistry · 2024Article
- Article
- Article
- Article
- An updated phylogeography and population dynamics of porcine circovirus 2 genotypes: are they reaching an equilibrium?Frontiers in microbiology · 2024Article
- Genetic diversity of porcine circoviruses 2 and 3 circulating among wild boars in the Moscow Region of Russia.Frontiers in veterinary science · 2024Article
- Field evaluation of novel plant-derived porcine circovirus type 2 vaccine related to subclinical infection.Veterinary medicine and science · 2023Article
- Revisiting Porcine Circovirus Infection: Recent Insights and Its Significance in the Piggery Sector.Vaccines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Porcine circovirus type 2 (PCV2) vaccination has been effective in protecting pigs from clinical disease and today is used extensively. Recent studies in vaccinated populations indicate a major PCV2 genotype shift from the predominant PCV2 genotype 2b towards 2d. The aims of this study were to determine the ability of the commercial inactivated PCV2a vaccine Circovac® to protect pigs against experimental challenge with a 2013 PCV2d strain and prevent transmission. Thirty-eight pigs were randomly divided into four groups with 9-10 pigs per group: NEG (sham-vaccinated, sham-challenged), VAC (PCV2a-vaccinated, sham-challenged), VAC+CHAL (PCV2a-vaccinated and PCV2d-challenged), and CHAL (sham-vaccinated, PCV2d-challenged). Vaccination was done at 3weeks of age using Circovac® according to label instructions. The CHAL and VAC+CHAL groups were challenged with PCV2d at 7weeks of age and all pigs were necropsied 21days post-challenge (dpc). The VAC-CHAL pigs seroconverted to PCV2 by 21days post vaccination (dpv). At PCV2d challenge on 28dpv, 3/9 VAC and 1/9 VAC+CHAL pigs were seropositive. NEG pigs remained seronegative for the duration of the study. Vaccination significantly reduced PCV2d viremia (VAC+CHAL) at dpc 14 and 21, PCV2d fecal shedding at dpc 14 and 21 and PCV2d nasal shedding at dpc 7, 14 and 21 compared to CHAL pigs. Vaccination significantly reduced mean PCV2 antigen load in lymph nodes in VAC+CHAL pigs compared to CHAL pigs. When pooled serum or feces collected from VAC+CHAL and CHAL pigs at dpc 21 were used to expose single-housed PCV2 naïve pigs, a pooled fecal sample from CHAL pigs contained infectious PCV2 whereas this was not the case for VAC+CHAL pigs suggesting reduction of PCV2d transmission by vaccination. Under the study conditions, the PCV2a-based vaccine was effective in reducing PCV2d viremia, tissue loads, shedding and transmission indicating that PCV2a vaccination should be effective in PCV2d-infected herds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.